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Abstract
Background: Transmembrane protein 106B (TMEM106B) has been identified as a risk factor for frontotemporal
lobar degeneration, which is the second most common form of progressive dementia in people under 65 years
of age. Mutations in charged multivesicular body protein 2B (CHMP2B), which is involved in endosomal protein
trafficking, have been found in chromosome 3-linked frontotemporal dementia. Despite the number of studies on
both CHMP2B and TMEM106B in the endolysosomal pathway, little is known about the relationship between
CHMP2B and TMEM106B in the endosomal/autophagy pathway.
Results: This study found that endogenous TMEM106B was partially sequestered in CHMP2B-positive structures,
suggesting its possible involvement in endosomal sorting complexes required for transport (ESCRT)-associated
pathways. The role of single nucleotide polymorphisms of TMEM106B (T185, S185, or S134N) in the ESCRT-
associated pathways were characterized. The T185 and S185 variants were more localized to Rab5-/Rab7-positive
endosomes compared with S134N, while all of the variants were more localized to Rab7-positive endosomes
compared to Rab5-positive endosomes. T185 was more associated with CHMP2B compared to S185. Autophagic
flux was slightly reduced in the T185-expressing cells compared to the control or S185-expressing cells. Moreover,
T185 slightly enhanced the accumulation of EGFR, impairments in autophagic flux, and neurotoxicity that were
caused by CHMP2BIntron5 compared to S185-expressing cells.
Conclusions: These findings suggest that the T185 variant functions as a risk factor in neurodegeneration with
endolysosomal defects. This study provides a better understanding of pathogenic functions of TMEM106B, which is
a risk factor for the progression of neurodegenerative diseases that are associated with endosomal defects in the
aged brain.
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Introduction
Frontotemporal lobar degeneration (FTLD) is the third
most common neurodegenerative disease, after Alzheimer’s
disease and Parkinson’s disease [1]. FTLD is a genetically,
clinically, and pathologically heterogeneous disease with
symptoms that include progressive aphasia and changes in
personality and social behavior. Interestingly, about 40 % of
patients with FTLD show a family history of the disease,
which indicates that FTLD has a strong genetic compo-
nent [2]. Indeed, several disease-associated genes, such
as microtubule-associated protein tau (MAPT), progra-
nulin (PGRN), charged multivesicular body protein 2B
(CHMP2B), chromosome 9 open reading frame 72
(C9ORF72), and valosin-containing protein (VCP), have
been identified as causative or risk factors for FTLD
[3, 4]. A recent genome-wide association study of FTLD
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with TAR DNA-binding protein 43 (TDP-43) inclusions
(FTLD-TDP), or FTLD with a PGRN mutation, showed
that transmembrane protein 106B (TMEM106B), which
encodes a transmembrane protein with unknown function,
increases the risk of the disease or of the development of
cognitive impairment in patients with amyotrophic lateral
sclerosis [5, 6]. Furthermore, its expression changes in
patients with Alzheimer’s disease [7, 8]. Linkage disequilib-
rium studies have shown that the top three single-
nucleotide polymorphisms (SNPs) (rs6966915, rs1020004,
and rs1990622) in the noncoding region of TMEM106B
are associated with FTLD-TDP, and TMEM106B mRNA
and protein expression are significantly increased in the
frontal cortex of patients with FTLD-TDP compared with
controls, suggesting its importance in normal brain func-
tion [9]. Moreover, the S134N and p.(T185 or S185) vari-
ants in the coding region have been identified in patients
with FTLD [7]. rs3173615 (p.185S) was found to be in per-
fect linkage disequilibrium with rs1990622, which is one of
the top three SNPs of TMEM106B. This suggests that
S185 is a protective isoform while the T185 form confers
risk. Protein levels of S185 are reportedly lower than T185
because of its rapid rate of protein degradation in mamma-
lian cells [10]. However, the association of S134N in neu-
rons with disease has not been fully addressed [7]. More
recently, TMEM106B has been shown to be a genetic
modifier in patients with FTLD with C9ORF72 expansions,
which are the most common known genetic cause of fron-
totemporal dementia (FTD), amyotrophic lateral sclerosis,
and the combination of these diseases [4, 11]. Therefore,
TMEM106B is a major genetic modifier in patients with
FTLD with a PGRN mutation or C9ORF72 hexanucleotide
repeat expansions [2, 3].
TMEM106B is a type-II glycoprotein localized to late
endosomes/lysosomes, and its overexpression causes en-
larged lysosomes and impaired endo-lyososomal degrad-
ation [12, 13]. The interaction of TMEM106B and
MAP6 has been reported to regulate the dendritic traf-
ficking of lysosomes in cultured primary hippocampal
neurons, which suggests that TMEM106B plays a crucial
role in the regulation of protein trafficking through
MAP6 in the dendrites of polarized neurons [14]. More
recently, TMEM106B has been shown to regulate lyso-
some size, motility, and stress responses and interact
with endocytic proteins, such as the μ1 subunit of AP2
(AP2M1) or clathrin heavy chain (CLTC), indicating its
importance in the regulation of trafficking in the endoly-
sosomal pathway [15].
The endosomal sorting complexes required for trans-
port (ESCRT) are heteromeric protein complex composed
of ESCRT-0, -I, -II, or -III. These complexes have been
shown to regulate protein trafficking in the endolysosomal
pathway and the fusion of autophagosomes with lyso-
somes in the autophagy pathway [16, 17]. Interestingly,
mutations in CHMP2B, which is a major component of
ESCRT-III, have been identified in chromosome 3-linked
FTD (FTD-3), and the disease-associated CHMP2BIntron5
causes defects in protein trafficking in the endolysosomal
pathway and in the accumulation of autophagosomes due
to an impairment in the fusion of autophagosomes with
lysosomes [18, 19]. It has also been shown that transgenic
mice expressing FTD-3-linked CHMP2BIntron5 in their
forebrain show defects in social behavior, which is a
symptom exhibited by patients with FTLD [20].
CHMP2B has also been shown to regulate the matur-
ation and maintenance of dendritic spines, synaptogenesis,
and synaptic potentiation during chemical long-term po-
tentiation [21, 22]. Intriguingly, both FTLD-associated
CHMP2B and TMEM106B have been identified in the
endolysosomal pathway, and both are known to regulate
dendritic morphology in neurons [21, 23].
Although a number of recent studies have examined
the cellular functions of TMEM106B in lysosomes, the
function of TMEM106B in ESCRT-associated endoso-
mal and autophagy pathways has not been elucidated.
Furthermore, whether the increased expression of
TMEM106B modulates CHMP2BIntron5-mediated endo-
somal defects and neurotoxicity is unknown. In this
study, we examined whether TMEM106B variants were
associated with the ESCRT pathway and whether dis-
ease-associated TMEM106B expression affected the cellular
pathogenic effects of CHMP2BIntron5 in cultured cortical
neurons. We found that the T185 variant associated more
with CHMP2B and reduced autophagic flux compared to
S185. Furthermore, T185 expression enhanced the
CHMP2BIntron5-mediated endosomal/autophagic defects
and neurotoxicity to a greater extent than S185. The find-
ings of this study suggest that the T185 variant of
TMEM106B is a risk factor for neurodegeneration associ-
ated with endosomal defects.
Results
Localization of endogenous TMEM106B to CHMP2BWT- or
CHMP2BIntron5-positive structures in cultured cortical
neurons
In order to determine whether TMEM106B was involved
in the ESCRT-associated endosomal pathway, we first ex-
amined the cellular localization of TMEM106B in
CHMP2BWT- and CHMP2BIntron5-expressing cortical neu-
rons [23]. As shown in Fig. 1a, endogenous TMEM106B
was partially colocalized to CHMP2B-positive endosomal
structures. Interestingly, some TMEM106B-positive parti-
cles were adjacent to CHMP2B-positive structures, which
indicated its possible association with the ESCRT complex
in the endosomal pathway. In order to examine its as-
sociation with CHMP2B in pathological conditions
that are associated with the dysfunctional ESCRT com-
plex, we investigated its localization in FTD-3-linked
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CHMP2BIntron5-expressing neurons [23, 24]. Endogenous
TMEM106B was sequestered into abnormal CHM
P2BIntron5 aggregates (Fig. 1b). Interestingly, CHMP
2BIntron5-expressing neurons contained larger TMEM
106B particles that were associated with CHMP2BIntron5-
positive particles, which raised the possibility of a
pathogenic effect of dysfunctional ESCRT-induced
neurodegeneration.
Greater localization of T185 and S185 to endosomal
structures compared to S134N
The ESCRT complex is involved in the regulation of pro-
tein trafficking from early endosomes to late endosomes
[25, 26]. If TMEM106B is involved in the ESCRT-
associated endosomal pathway, it may be localized to
Rab5- and Rab7-positive endosomes and function in as-
sociation with the ESCRTs. We generated SNP variants
of TMEM106B [p(T185, S185, and S134N], which have
been identified in patients with FTLD, in order to better
understand their functional significance and investigate
differences in their cellular effects in endosomal path-
ways in the same cellular model system. In order to
characterize each TMEM106B SNP variant in the
endosomal pathway, the protein expression of each flag-
tagged TMEM106B SNP (T185, S185, and S134N) was
examined in HEK293T cells. Their levels of protein ex-
pression were similar 24 h after transfection in our cellu-
lar system (Fig. 1c). In order to examine their cellular
localization in cortical neurons, each flag-tagged
TMEM106B SNP was co-transfected with green fluores-
cent protein (GFP)-Rab5, an early endosomal marker, or
GFP-Rab7, a late endosomal marker. As shown in
Fig. 1d–f, all of the variants were more localized to Rab7-
positive late endosomes compared to Rab5-positive early
endosomes. However, the S134N variant was localized less
to both early and late endosomes compared to the T185
and S185 variants, even though its levels of protein ex-
pression were similar to the levels of the other variants
(Fig. 1b–c). This suggests that the T185 and S185 variants
might affect the ESCRT-mediated endosomal pathway.
Greater association of the T185 variant with CHMP2B
compared to the S185 variant
In order to distinguish the effects of T185 from S185 in
ESCRT-associated endosomal pathways and autophagy
pathways, we examined their association with CHMP2B,
Fig. 1 TMEM106B was localized to CHMP2B-positive structures, and the T185, S185, and S134N SNPs of TMEM106B were localized to Rab5- and
Rab7-positive endosomes. a Confocal images showing the partial colocalization of endogenous transmembrane protein 106B (TMEM106B) and
either charged multivesicular body protein 2B (CHMP2B)WT or CHMP2BIntron5 (CHMP2BIn5). Flag-tagged CHMP2BWT and (b) flag-tagged CHMP2BIn5
were expressed in cultured cortical neurons. Twenty-four hours after transfection, the cells were fixed and stained with anti-flag and anti-TMEM106B
antibodies. The arrow indicates the colocalization of TMEM106B and CHMP2B. Scale bar: 10 μm. c Each flag-tagged TMEM106B single-nucleotide
polymorphism (SNP; T185, S185, and S134N) was transfected into HEK293T cells. Twenty-four h after transfection, western blot analyses were performed
with an anti-Flag or anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) antibody. GAPDH was used as a loading control. Each flag-tagged
TMEM106B SNP (T185, S185, and S134N) was cotransfected with either green fluorescent protein (GFP)-Rab5 (d) or GFP-Rab7 (e) in cultured cortical
neurons. Twenty-four hours after transfection, the neurons were fixed and stained with an anti-flag antibody. f The coefficients of colocalization were
measured and analyzed with the ImageJ program (Colocalization Indices). The values are presented as the mean ± standard error of the mean (SEM)
of three independent replicates. One-way analysis of variance (ANOVA) followed by Tukey’s multiple comparisons test; *p < 0.05, ***p < 0.001; ns,
not significant
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a component of the ESCRT-III complex that regulates
protein trafficking and autophagic degradation [25].
Flag-tagged T185 and S185 were expressed in HEK293T
cells. A protein co-immunoprecipitation analysis was
performed with an anti-flag antibody, and a western blot
analysis was performed with anti-CHMP2B and anti-flag
antibodies. As shown in Fig. 2a–b, T185 and S185 were
partially associated with endogenous CHMP2B. S185
was less associated with CHMP2B compared to T185
although protein stability is similar between T185 and
S185 (Additional file 1: Figure S1). In order to further
examine these associations in cortical neurons, we ex-
amined the cellular localization of T185 and S185 in cor-
tical neurons expressing flag-tagged T185 or S185. The
neurons expressing T185 or S185 were fixed and then
stained with anti-flag and anti-CHMP2B antibodies. As
shown in Fig. 2c–d, endogenous CHMP2B was partially
localized with T185 and S185. Our colocalization
Fig. 2 The T185 variant of TMEM106B was more associated with endogenous CHMP2B and reduced autophagic flux compared to the S185
variant. a Flag-tagged T185 or Flag-S185 was transfected into the HEK293T cells. Twenty-four to 48 h after transfection, a protein coimmunoprecipitation
assay was performed with an anti-flag antibody. Western blot analyses were performed with an anti-CHMP2B or anti-flag antibody. b The bar graph
represents the percentage of interaction of T185 or S185 with endogenous CHMP2B. For quantification, the band intensity of CHMP2B from the
immunoprecipitation samples was normalized to that of either flag-T185 or flag-S185. The values are presented as the mean ± SEM of three independent
replicates. Student’s t-test, **p< 0.01 c Each flag-tagged TMEM106B SNP (T185 or S185) was transfected into cultured cortical neurons. Twenty-four hours
after transfection, the neurons were fixed and stained with an anti-flag antibody and anti-TMEM106B antibody. The arrows indicate the colocalization of
CHMP2B with either T185 or S185. Scale bar: 20 μm. d The bar graph indicates the colocalization of endogenous CHMP2B with either T185 or S185 of
TMEM106B. The coefficients of colocalization were measured and analyzed with the ImageJ program (Colocalization Indices). The values are presented as
the mean ± SEM of three independent replicates. Student’s t-test; **p< 0.001. e Flag-tagged T185 or Flag-tagged S185 was transfected into HEK293T cells.
Twenty-four h after transfection, the transfected or control cells were incubated with or without ammonium chloride (NH4Cl) for 24 h. The cell lysates were
then subjected to western blot analyses with an anti-flag, anti-microtubule-associated protein 1A/1B-light chain 3 (LC3), or anti-GAPDH antibody. f The
autophagic flux indicates the difference in the LC3-II levels in the presence and absence of NH4Cl. The autophagic flux ratio in the T185-
or S185-expressing cells was normalized to that of the control cells. The values are presented as the mean ± SEM of three independent
replicates. One-way ANOVA followed by Tukey’s multiple-comparisons test; **p < 0.01, ***p < 0.001
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analysis showed that T185 was associated more with
CHMP2B, in line with our co-immunoprecipitation data
(Fig. 2c–d).
Autophagic flux was slightly reduced in cells expressing
T185, but not in cells expressing S185
If TMEM106B associates with CHMP2B, what is its role
in the ESCRT-involved endolysosomal pathway? Because
TMEM106B associates with CHMP2B in endosomal
pathways and functions in lysosomes, TMEM106B might
be involved in autophagy with reference to its associ-
ation with CHMP2B [27–29]. In order to investigate this
question, we examined whether the expression of the
TMEM106B variants affected autophagic flux. In order
to measure autophagic flux, the levels of microtubule-
associated protein 1A/1B-light chain 3 (LC3)-II in cells
expressing T185 or S185 in the presence or absence of
the lysosomotrophic reagent ammonium chloride
(NH4Cl) were quantified in a western blot analysis
[30, 31]. As shown in Fig. 2e–f, cells expressing T185
showed a slight reduction in autophagic flux compared to
cells expressing S185. These results suggested that the
enhanced sequestration of CHMP2B might reduce au-
tophagic flux.
T185 was more sequestered in CHMP2BIntron5-positive
aggregates than S185
Next, we examined the effects of diseases that are associ-
ated with TMEM106B as a risk factor in CHMP2BIntron5-
mediated neurotoxicity. First, we examined the associations
of T185 and S185 and the FTD-linked mutant CHMP2BIn-
tron5. Flag-tagged T185 and S185 were transfected with
CHMP2BIntron5-cMyc. Co-immunoprecipitation was per-
formed with an anti-flag antibody, and a western blot ana-
lysis was done with an anti-cMyc antibody. As shown in
Fig. 3a–b, the T185 variant was more associated with
CHMP2BIntron5 than S185. We then examined the cellular
localization of flag-tagged T185 and S185 in cortical neu-
rons expressing CHMP2BIntron5. T185 was mostly seques-
tered into abnormal CHMP2BIntron5-positive aggregates,
while S185 was partially sequestered into aggregates
(Fig. 3c–d). These results suggested the involvement of
Fig. 3 T185 was sequestered more in CHMP2BIntron5-positive aggregates. a CHMP2BIntron5-cMyc (CHMP2BIn5-cMyc) was cotransfected with either
Flag-tagged T185 or S185 into the HEK293T cells. Twenty-four to 48 h after transfection, the cell lysates were used for coimmunoprecipitation with
an anti-flag antibody. Western blot analyses were performed with anti-cMyc or anti-flag antibodies. b The bar graph represents the percentages
of interaction of T185 or S185 with CHMP2BIn5. For quantification, the band intensity of CHMP2BIn5 from the immunoprecipitation samples was
normalized to that of either flag-tagged T185 or flag-S185. The values are presented as the mean ± SEM of three independent replicates. Student’s
t-test, *p < 0.05. c Each flag-tagged TMEM106B SNP (T185 or S185) was cotransfected with CHMP2BIn5-cMyc into cultured cortical neurons.
Twenty-four hours after transfection, the neurons were fixed and stained with an anti-flag antibody and anti-cMyc antibody. The arrows indicate
the colocalization of CHMP2B with either T185 or S185. Scale bar: 20 μm. d The bar graph indicates the colocalization of CHMP2BIn5 with either
the T185 or S185 isoform of TMEM106B. The coefficients of colocalization were measured and analyzed with the ImageJ program (Colocalization
Indices). The values are presented as the mean ± SEM of three independent replicates. Student’s t-test; ***p < 0.001
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T185 in the CHMP2BIntron5-mediated cellular defects and
neurotoxicity.
T185 slightly enhanced the CHMP2BIntron5-mediated
endosomal/autophagic defects compared to S185
The results of our cellular study showed that, among the
variants of TMEM106B, T185 was associated more with
CHMP2B and reduced autophagic flux to a greater extent
than S185 (Figs. 2 and 3). Therefore, we wanted to com-
pare the effects of T185 and S185 on CHMP2BIntron5-me-
diated neurotoxicity. The expression of TMEM106B is
increased in the brains of patients with FTLD [32, 33]. We
next investigated whether T185 or S185 expression
affected the neurotoxicity that is mediated by the FTD-3-
linked mutant CHMP2B [19, 23]. Our previous report
showed that the degradation of the epidermal growth fac-
tor receptor (EGFR) was delayed in CHMP2BIntron5-ex-
pressing cells [13, 19, 23].
In order to examine whether T185 or S185 affects the
delayed degradation of the EGFR by CHMP2BIntron5,
flag-tagged T185, flag-tagged S185, or an empty vector
were coexpressed with CHMP2BIntron5-cMyc, and an
EGFR degradation assay was performed. As reported
previously, EGFR protein in CHMP2BIntron5-expressing
cells remained at significant levels 30 and 60 min after
EGF treatment (Fig. 4a–b) [23]. However, T185 further
enhanced the accumulation of EGFR that was induced
by CHMP2BIntron5 expression 30 and 120 min after EGF
Fig. 4 T185 slightly enhanced FTD-linked CHMP2BIntron5-mediated endo/autosomal defects and neurotoxicity, compared to S185. a GFP (CTL),
Flag-tagged T185, Flag-tagged S185, and/or CHMP2BIn5 were transfected into the HEK293T cells. Twenty-four to 48 h after transfection, the cells
were incubated only with DMEM for 3 h and then treated with human epidermal growth factor (100 ng/mL) and cycloheximide (CHX, 30 μg/mL)
for the indicated times (0, 30, 60, 120, or 240 min). Western blot analyses were conducted on the cell lysates with an anti-flag, anti-epidermal
growth factor receptor (EGFR), anti-cMyc, or anti-GAPDH antibody. b The EGFR degradation was normalized to the levels of GAPDH. The graph
represents the percentage of EGFR degradation that occurred during the indicated time. The percentage of EGFR degradation in each sample
was normalized to that of EGFR in the control cells. The values are presented as the mean ± SEM of three independent replicates. One-way
ANOVA followed by Tukey’s multiple-comparisons test; ***p < 0.001. c CHMP2BIn5-cMyc was cotransfected with or without flag-tagged T185 or
flag-tagged S185 into HEK293T cells. Twenty-four to 48 h after transfection, the transfected cells or control cells were incubated with ammonium
chloride (NH4Cl) or without it for 24 h, and then the cell lysates were subjected to western blot analyses with an anti-flag, anti-cMyc, anti-LC3, or
anti-GAPDH antibody. d Autophagic flux indicates the difference in the LC3-II levels in the presence and in the absence of NH4Cl. The autophagic
flux in the CHMP2BIn5-cMyc expressing cells with (or without) T185 or S185 expression was normalized to that of the control cells to represent
autophagic ratio compared to the control cells. The values are presented as the mean ± SEM of three independent replicates. One-way ANOVA
followed by Tukey’s multiple-comparisons test; ***p < 0.001. e Flag-tagged T185, flag-tagged S185 or/and CHMP2BIntron5 were cotransfected with
GFP into cultured cortical neurons. The surviving neurons were counting the GFP-positive and propidium iodide (PI)-negative cells. The cell
survival graph indicates the survival percentages of neurons expressing Flag-tagged T185 and/or CHMP2BIntron5-cMyc and GFP. The values are
presented as the mean ± SEM of three independent replicates. One-way ANOVA followed by Tukey’s multiple-comparisons test; ***p < 0.001
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treatment (10 ng/mL), and the expression of T185
caused a slight delay in EGFR degradation compared to
S185 (Fig. 4a–b). We next investigated whether T185 or
S185 could modulate the reduction in autophagic flux
that was caused by CHMP2BIntron5. The levels of LC-II
in the presence or absence of NH4Cl in CHMP2B
Intron5-
cMyc-expressing cells with (or without) flag-tagged
T185 or flag-tagged S185 were quantified in a western
blot analysis. As shown in Fig. 4c–d, T185 amplified/
enhanced the CHMP2B-induced reduction in autophagic
flux to a greater degree than S185. These findings sug-
gested that T185 enhanced the endosomal defects in




Although TMEM106B is considered a risk factor for
FTLD-TDP and FTLD with C9ORF72 expansions, little
is known about its cellular pathogenic effects on
CHMP2BIntron5-mediated neurodegeneration. Thus, to
investigate whether T185 affected neuronal survival and
CHMP2BIntron5-mediated neurotoxicity, flag-tagged T185
or flag-tagged S185 were co-transfected with GFP into
mature cortical neurons, and the surviving neurons were
counted 2–3 days later. As shown in Fig. 4e, T185 or S185
expression did not cause significant neuronal death
24–72 h after transfection in the cultured cortical
neurons. However, T185, but not S185, significantly
increased CHMP2BIntron5 expression-induced cell death.
These results suggest that the T185 variant of
TMEM106B functions as a risk factor that might enhance
neuronal toxicity associated with neurodegeneration with
endosomal defects, such as ESCRT dysfunction-associated
neurodegeneration.
Discussion
TMEM106B, which is localized to late endosomes and
lysosomes, has been implicated in FTLD-TDP, which is
associated with a PGRN mutation [7, 9], and its func-
tions have been mainly characterized in lysosomes. Both
TMEM106B and CHMP2B are localized to late endo-
somes and regulate neuronal morphology in polarized
postmitotic neurons, suggesting their possible involve-
ment in neuronal function [14, 21, 22]. However, little is
known about their functional associations and the effects
of diseases that involve TMEM106B in the ESCRT-
mediated endosomal pathway and neurodegeneration
with endosomal defects, such as ESCRT dysfunction.
Here we present novel evidence of the association be-
tween TMEM106B and CHMP2B, and the effects of
TMEM106B on CHMP2BIntron5-mediated endosomal/
autophagic defects and neurotoxicity. Based on the re-
sults of our cellular studies, endogenous TMEM106B
was associated with CHMP2B-positive endosomes and
early/late endosomal structures. Moreover, endogenous
TMEM106B was mostly sequestered into disease-mutant
CHMP2BIntron5-positive aggregates in cultured cortical
neurons. The results of this study indicated that
TMEM106B was involved in the ESCRT-mediated path-
way and that its functional loss through abnormal seques-
tration contributed to the disease phenotype associated
with FTD-3-linked CHMP2BIntron5. A recent study
showed that loss of TMEM106B reduced dendritic lyso-
somes and altered dendritic arborization [14]. Indeed,
CHMP2BIntron5 expression causes dendritic retraction and
defects in the maturation of dendritic spines, which sug-
gests that it may be linked to TMEM106B in the regula-
tion of dendritic morphology [21, 23]. Future detailed
characterizations of the functional association of
TMEM106B and CHMP2B in the regulation of dendritic
morphology and other neuronal functions will be needed.
Moreover, we investigated the effects of SNP variants
in the exon region of TMEM106B on the ESCRT-
mediated pathway. Among the variants of TMEM106B,
S134N was less localized to early/late endosomes com-
pared to T185 or S185, which indicated that the T185
and S185 forms affect the ESCRT-mediated pathway. Al-
though a previous in silico analysis predicted the re-
duced stability of S134N [7], our western blot analysis
showed no significant differences in the protein expres-
sion levels of S134N and the other variants, at least in
our cell culture model system. Detailed functional char-
acterizations of the involvement of S134N in the cellular
pathogenesis of FTLD are needed.
Our co-immunoprecipitation and colocalization ana-
lyses showed that T185 was associated more with
CHMP2B and CHMP2BIntron5 compared to S185. This
was unexpected because previous studies have reported
that S185 degrades faster than T185, potentially due to
differences in N-glycosylation at residue N183 [10].
However, 24–48 h after transfection in our cultured sys-
tem, neither protein expression levels nor protein stability
of T185 and S185 significantly differed from one another
(Fig 1c, Additional file 1: Figure S1). Furthermore, the co-
immunoprecipitation results clearly showed that CHMP2B
associated less with the same amount of S185 compared
with T185, which indicated that an amino-acid substitu-
tion (T- > S) might affect their protein structure and
protein-protein interactions.
We also found that T185 expression reduced autopha-
gic flux. The role of TMEM106B in the autophagy path-
way remains unclear, although it is known that
TMEM106B is localized to late endosomes/lysosomes.
Indeed, it is well known that late endosomes can fuse with
autophagosomes in autophagic maturation and that many
lysosomal proteins and late endosomal proteins, such as
ESCRT-III protein and Rab7 GTPase, are involved in this
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step of the autophagic process [28, 34–36]. Thus, the dy-
namic and transient interaction of the ESCRT complex,
including the interaction of CHMP2B with TMEM106B,
might affect the autophagic process. However, the greater
association of T185 with CHMP2B might impair the nor-
mal steady state of the autophagic process compared to
S185, which would result in reduced autophagic flux.
Moreover, TMEM106B expression has been reported to
cause the translocation of transcription factor EB, which
controls autophagy and lysosomal biogenesis under stress,
further implicating the possible link between TMEM106B
and autophagy [15]. Future studies designed to elucidate
the putative role of TMEM106B in autophagic regulation
will provide additional insights into the mechanisms
involved.
According to the results of our cellular studies in cul-
tured cortical neurons, T185 enhanced CHMP2BIntron5
mutant-mediated endo/autosomal defects and neurotox-
icity compared to S185, thus suggesting that TMEM106B
might also be a risk factor in ESCRT-dysfunctional neuro-
degeneration. Increased levels and disordered expression
patterns of TMEM106B have been reported in the brains
of patients with FTLD [37]. More recently, TMEM106B
has been reported as a genetic modifier of disease in car-
riers of C9ORF72 expansions, which are also involved in
the endolysosomal pathway [2, 4]. A growing body of evi-
dence has shown that endolysosomal dysfunctions are
closely associated with the cellular pathogenesis of several
forms of FTLD [38]. Although TMEM106B was first iden-
tified in FTLD-TDP, SNPs in the coding region of
TMEM106B might affect cellular signaling and protein-
protein interactions that are involved in the endo-
lysosomal pathway. Therefore, it is possible that
TMEM106B might have more general effects on neuro-
degenerative diseases associated with defects of the
endolysosomal pathway, such as Alzheimer’s disease
and Parkinson’s disease, than previously believed. Fu-
ture work employing transgenic mouse models or in-
duced pluripotent stem cell-derived cellular models will
be essential for revealing in vivo physiological and
pathological functions of TMEM106B and its SNPs.
The findings of the present study contribute to a better
understanding of the role of TMEM106B in the cellular
pathogenesis of neurodegenerative diseases that are as-
sociated with the endolysosomal and autophagy path-
way and as a risk factor for these diseases.
Conclusion
The results of this study provide novel evidence of an as-
sociation between TMEM106B and the ESCRT-III com-
plex protein, CHMP2B. In addition, we show that
TMEM106B affects the ESCRT-mediated endosomal and
autophagy pathways. Our functional characterization of
the SNPs of TMEM106B showed that in comparison to
the S185 isoform, the T185 isoform associated more with
CHMP2B and reduced autophagic flux to a greater extent,
thus enhancing the CHMP2BIntron5-induced endosomal/
autophagic defects and neurodegeneration. Further
characterization of TMEM106B in the ESCRT-mediated
pathway and autophagy pathway may open up new ave-
nues for the development of disease-modifying therapies
in neurodegeneration that is associated with endolysoso-
mal defects, as well as in FTLD.
Methods
DNA constructs
The human TMEM106B gene was cloned by nested poly-
merase chain reaction (PCR) from the cDNA of HeLa
cells, and the TMEM106B mutations were then generated
with recombinant PCR by using specific primer sets
(Nested PCR primers: 1st set, Forward: 5′-ccttgtcttaacta-
caaac-3′, Reverse: 5′-cattgagagtataggaaatatc-3′; 2nd set,
Forward: 5′-ctcctcagacatgggaaagtc-3′, Reverse: 5′-ctttaaat
ccatctcttccag-3′; T185, 5′-aaacaacataagcattattggt-3′, Re-
verse: 5′-accaataatgcttatgttgtt-3′; S134N, Forward: 5′-gcc
tatgtcaattatgatgtt-3′, Reverse: 5′-aacatcataattgacataggc-3′).
For the mammalian expression, the DNA fragments were
amplified with specific sets of primers (Forward: 5′-gaa
gatctggccaccatgggaaagtctctttct-3′ and Reverse: 5′-gctcta
gattactgttgtggctgaag -3′) and then subcloned into a
3XFLAG CMV 7.1 vector by using a BglII-XbaI site.
Cell cultures and transfection
Primary cortical neurons were isolated from embryonic
day 18 ICR mouse (Samtako Co., Ltd., Osan, Korea and
DBL, Korea). HEK293T cells were grown in Dulbecco’s
Modified Eagle’s Medium (DMEM) (Thermo Fisher
Scientific Inc., Waltham, MA, USA) that was supple-
mented with 10 % fetal bovine serum (Thermo Fisher
Scientific Inc.) and 1 % Penicillin-Streptomycin (Thermo
Fisher Scientific Inc.) at 37 °C in 5 % CO2. Each plasmid
DNA was transfected with Lipofectamine 2000 (Thermo
Fisher Scientific Inc.) or Ca2+-phosphate reagents
(Clontech Laboratories, Inc., Mountain View, CA, USA)
in HEK293T cells or differentiated cortical neurons after
4–6 days in vitro, according to the manufacturer’s
protocol.
Immunocytochemistry, image analysis, and statistical
analysis
Transfected cells were fixed with 4 % paraformaldehyde
(Noblechem; #PAR500) for 10 min. For immunostaining,
the transfected cells were permeabilized with 0.1 % Triton
X-100 (Merck & Co., Inc., Kenilworth, NY, USA; #108603)
and then blocked with 3 % bovine serum albumin (Sigma-
Aldrich Co. LLC, St. Louis, MO, USA; #A7906) in
phosphate-buffered serum (Welgene, Inc., Daegu, Korea)
for 1 h at room temperature. The primary antibodies
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[anti-FLAG M2 (Sigma-Aldrich Co. LLC, F1804), anti-
CHMP2B (Abcam PLC, Cambridge, UK; ab33174), anti-
TMEM106B (Proteintech Group, Inc., Chicago, IL, USA;
#20995-1-AP), anti-cMyc (EMD Millipore, Billerica,
MA, USA; #06-549) and secondary antibodies (Jackson
ImmunoResearch Laboratories, Inc., West Grove, PA,
USA; #715-545-150, #715-165-150, #711-165-152, and
#711-485-152) were incubated for 1 h each at room
temperature. All of the photomicrographs were cap-
tured with a confocal microscope (Carl Zeiss AG, Jena,
Germany; LSM 510). Image analysis and colocalization
analyses were performed using ImageJ program (NIH) .
GraphPad Prism 5 was used for statistical analysis.
The values are presented as the mean ± SEM of three in-
dependent replicates. One-way ANOVA followed by
Tukey’s multiple-comparisons test for statistical analysis
of more than three data sets or Student-t-test for statis-
tical analysis of two groups was selected.
Coimmunoprecipitation and western blotting
Forty-eight h after transfection with the plasmid DNA,
the HEK293T cells were lysed with immunoprecipitation
lysis buffer [50 mM of Tris-HCl (pH 7.5), 150 mM of
NaCl, 1 % NP40, 0.5 % sodium deoxycholate, and protease
inhibitor (F. Hoffmann-La Roche AG, Basel, Switzerland)].
The total cell lysates were incubated with 3 μg of the anti-
FLAG antibody overnight at 4 °C and then incubated with
Protein G agarose beads for 7 h at 4 °C. Subsequently, the
protein complexes were washed with immunoprecipita-
tion lysis buffer three times at 4 °C. For the western blot-
ting, the samples were separated on 9–11 % sodium
dodecyl sulfate-polyacrylamide gel electrophoresis gels
and then transferred to polyvinylidene fluoride mem-
branes (F. Hoffmann-La Roche AG). After blocking with
5 % nonfat milk, the membranes were incubated with the
primary antibody and horseradish peroxidase-conjugated
anti-mouse or anti-rabbit secondary antibody.
Autophagic flux assay and quantification
To analyze autophagic flux, flag-tagged T185 or Flag-
S185 was transfected with (or without) CHMP2BIn5 into
HEK293T cells. Twenty-four hours after transfection,
the transfected or control cells were incubated with or
without ammonium chloride (NH4Cl) for 24 h. The cell
lysates were then subjected to western blot analyses
with an anti-flag, anti-microtubule-associated protein
1A/1B-light chain 3 (LC3), or anti-GAPDH antibody.
For quantification of autophagic flux, band intensity in
each sample of western blot was measured using the
ImageJ software. The difference in the LC3-II levels in
the presence and absence of NH4Cl in each group was
quantified from band intensity. Autophagic flux indi-
cates the difference in the LC3-II levels in the presence
and absence of NH4Cl. To compare the autophagic flux
of each sample compared to control, we normalized the
autophagic flux of each sample to that of the control
cells (Autophagic flux ratio, control = 1). The values are
presented as the mean ± SEM of three independent
replicates.
EGFR degradation assays and protein degradation assay
To assay EGFR degradation, 48 h after the transfection,
the cells were starved in DMEM alone for 3 h. Human
epidermal growth factor (100 ng/mL) and cycloheximde
(30 μg/mL) were incubated for the indicated times (30,
60, 120, or 240 min). For the protein degradation assay,
24 h after transfection, the cells were washed with
1XPBS and cycloheximide (30 μg/mL) and were incu-
bated for the indicated times (0, 24, or 48 h). The cell ly-
sates that were prepared in RIPA buffer were subjected to
western blotting with anti-EGFR, anti-FLAG, anti-MYC, or
anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
antibody and horseradish peroxidase-conjugated anti-
mouse or -rabbit secondary antibody.
Additional file
Additional file 1: Figure S1. (A) Flag-tagged T185 or flag-tagged S185
was transfected into HEK293T cells. Twenty-four hours after transfection,
the cells were washed with 1XPBS and cycloheximide (CHX) (30 μg/mL)
and incubated for the indicated times (0, 24, or 48 h). The cell lysates that
were prepared in RIPA buffer were subjected to western blotting with
anti-FLAG, or GAPDH antibody and horseradish peroxidase-conjugated
anti-mouse or anti-rabbit secondary antibody. (B) Levels of EGFR was
normalized to that of GAPDH for the indicated times (0, 24, or 48 h) in
the presence of CHX. Bar graph represents the EGFR degradation ratio
compared to the level of EGFR at 0 h after CHX treatment in T185 or
S185 expressing cells. The values are presented as the mean ± SEM of
three independent replicates. Student t-test; ns, not significant. (TIF 1336 kb)
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